The latest news about Montara

Montara’s BrainOnly platform is designed to prevent peripheral side effects and concentrate neurological drugs’ activity in the brain via two-drug combination therapies, comprising its non−brain-penetrant “universal” peripheral blocker development candidate, MT1110, and a brain-penetrant target-specific drug. Montara will enter the clinic in H2 2026 to study an MT1110-everolimus combination, called MTX-E1, for the treatment of TSC-related epilepsy and other mTOR-driven CNS diseases.

Montara Therapeutics awarded $3.3 million non-dilutive MJFF grant to develop BrainOnly™ Parkinson’s therapy targeting LRRK2, a genetically validated target with major drug development challenges. New collaboration to use Montara’s BrainOnly platform to create a next-generation brain-selective LRRK2 inhibitor that avoids the irreversible toxicity from unselective peripheral activity.

Syndicate strengthened with new investors and increased commitments from all existing investors. Total Series Seed funding reaches $28M to advance lead epilepsy program to IND, progress neurodegeneration program to development candidate (DC), and accelerate a third undisclosed program. Troy Wilson joins as Chairman of the Board, bringing extensive leadership, operating, and financing experience.

This Endpoints News article explores the creation of Montara Therapeutics by Kevan Shokat and Nicholas Hertz after selling their first neuro startup to AbbVie.